Oxford Biomedica (OXB.L)
A leader in the viral vector manufacturing sector, providing essential development and production services for advanced cell and gene therapy treatments.
What Oxford Biomedica does
Oxford Biomedica is a gene and cell therapy contract development and manufacturing organization (CDMO) that specializes in the development and production of viral vectors. The company partners with biopharmaceutical companies to support the development and commercialization of gene-modified cell therapies and in vivo gene therapies.
Themes: cell therapy, gene therapy, viral vector manufacturing, biotech manufacturing services
Fundamentals
- Price£5.61 as of 2026-08-03 close
- Market capn/a company fundamentals are not available for UK-listed companies in our data
- 1-year return+20.8% 2025-08-01 close £4.65 → 2026-08-03 close £5.61
- P/En/a company fundamentals are not available for UK-listed companies in our data
- Net marginn/a company fundamentals are not available for UK-listed companies in our data
- Gross marginn/a company fundamentals are not available for UK-listed companies in our data
- ROEn/a company fundamentals are not available for UK-listed companies in our data
- Debt / equityn/a company fundamentals are not available for UK-listed companies in our data
- Revenue growth (YoY)n/a company fundamentals are not available for UK-listed companies in our data
- Revenue CAGR (3y)n/a company fundamentals are not available for UK-listed companies in our data
- Betan/a we do not track a market benchmark for UK-listed companies
Dividend: company fundamentals are not available for UK-listed companies in our data.
How Oxford Biomedica looks technically
Oxford Biomedica (OXB.L) is trading 13.2% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 32 trading days ago — a "death cross", a bearish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 7, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 38, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 10 trading days ago (its momentum flipped negative). It made a new 20-day low about 4 trading days ago. It is 41.7% below its highest point of the past year. Trading volume is unusually light — only about 0% of its 30-day average.
Trend
| Distance from the 200-day | -13.2% | it is trading 13.2% below its 200-day average, the long-term trend line — a long-term downtrend |
|---|---|---|
| 50-day moving average | £6.06 | its average price over the last 50 trading days — a short-term trend line — is £6.06 |
| 200-day moving average | £6.47 | its average price over the last 200 trading days — the long-term trend line — is £6.47 |
| Since the 50/200 cross | 32 sessions | its 50-day average crossed below its 200-day average about 32 trading days ago — a "death cross", a bearish long-term signal |
| Trend strength (14-day ADX) | 6.7 | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 7, below the 25 that marks a real trend) |
Momentum
| 14-day RSI | 38.3 | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 38, neither overbought (above 70) nor oversold (below 30) |
|---|---|---|
| Since the MACD crossed zero | 10 sessions | MACD, a trend-momentum gauge, turned bearish about 10 trading days ago (its momentum flipped negative) |
Range
| 52-week high | £9.62 | its highest closing price over the past year (about 252 trading days) was £9.62 |
|---|---|---|
| From the 52-week high | -41.7% | it is 41.7% below its 52-week high (its highest price of the past year) |
| Above the 52-week low | +107.4% | it is 107.4% above its 52-week low (its lowest price of the past year) |
| Below the 52-week high | 41.7% | it is 41.7% below its highest point of the past year |
| Since a 20-day breakout | 4 sessions | it made a new 20-day low about 4 trading days ago |
| Since a 55-day breakout | 4 sessions | it made a new 55-day low about 4 trading days ago |
| All-time high | £16.78 | its highest closing price on record is £16.78 (set on 2021-09-24) |
| From the all-time high | -66.6% | it is 66.6% below its all-time high |
| All-time low | £0.65 | its lowest closing price on record is £0.65 (set on 2013-07-22) |
| Above the all-time low | +763.1% | it is 763.1% above its all-time low |
Volatility
| Band width vs its own 6 months | 69th percentile | day-to-day price swings are about average versus its own recent 6-month history |
|---|---|---|
| Bollinger bands (20-day, ±2σ) | £5.30 – £5.99 – £6.67 | most of its recent trading has stayed between about £5.30 and £6.67 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles |
Volume
| Volume vs its 30-day average | 0.00× | trading volume is unusually light — only about 0% of its 30-day average |
|---|
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · trendless / choppy (low ADX) | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low · volume and relative volume
Based on daily closing prices as of 2026-08-03. Describes past price behavior only — informational, not financial advice.
Key risks (from latest filing)
["dependence on key customers and collaborative partners","inherent risks of complex viral vector manufacturing and regulatory compliance","competitive pressure in the CDMO market"]
Competitors & peers
- Lonza (LONN)
- Thermo Fisher Scientific (TMO)
- Catalent (CTLT)
- Samsung Biologics
- WuXi Biologics
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare OXB.L vs…
Frequently asked questions
What does Oxford Biomedica (OXB.L) do?
Oxford Biomedica is a gene and cell therapy contract development and manufacturing organization (CDMO) that specializes in the development and production of viral vectors. The company partners with biopharmaceutical companies to support the development and commercialization of gene-modified cell therapies and in vivo gene therapies.
Who are Oxford Biomedica's (OXB.L) competitors?
Notable peers of Oxford Biomedica (OXB.L) include Lonza, Thermo Fisher Scientific, Catalent, Samsung Biologics and WuXi Biologics. This peer set is informational only — not financial advice.
Is Oxford Biomedica (OXB.L) overbought or oversold right now?
Oxford Biomedica (OXB.L) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 38, in the neutral middle (as of 2026-08-03). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on OXB.L come from?
Fundamentals and prices come from market data. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data. Prices are delayed daily-close data.
Last updated 2026-08-03.
Informational only — NOT financial advice. All figures are delayed daily-close data from market data, shown with their as-of date.